-Timeline now= US 2018 + + / EU 2016 ............hopefully
.. In the US NO REVENUES not entering the US Market for CF. ........... for NTM 2018
"The Company expects results from the smaller confirmatory study by the first half of 2016 and results for the larger trial in 2017."
-In Europe after they file the average review timetable is 13 months for CF , NTM - dont be surprised if Europe look at the data and say/... We want more info too.....Stop the clock!!!
up 175% YTD Good Luck
13G filed by Point72 Asset Management, L.p Stevie Cohen !!! Stevie !!! Give us your guess when YOUR short is covered LOL !
by terry_insm • Aug 1, 2014 8:13 AM ......Guess the date of the next dilution Good Luck